Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000151225 | SCV000199088 | uncertain significance | not specified | 2014-08-21 | criteria provided, single submitter | clinical testing | The Pro82Leu variant in MYH6 gene has not been previously reported in individual s with cardiomyopathy or in large population studies. Computational prediction t ools and conservation analysis suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the Pro82Leu variant is uncertain. |
Labcorp Genetics |
RCV001041444 | SCV001205064 | likely benign | Hypertrophic cardiomyopathy 14 | 2024-01-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002453489 | SCV002738194 | uncertain significance | Cardiovascular phenotype | 2020-03-06 | criteria provided, single submitter | clinical testing | The p.P82L variant (also known as c.245C>T), located in coding exon 2 of the MYH6 gene, results from a C to T substitution at nucleotide position 245. The proline at codon 82 is replaced by leucine, an amino acid with similar properties. This alteration has been reported in a hypertrophic cardiomyopathy (HCM) cohort; however, clinical details were limited (Lopes LR et al. Heart, 2015 Feb;101:294-301). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |